Terry Chrisomalis | TalkMarkets | Page 3

Terry Chrisomalis

Pharma/Biotech Analyst
I am a graduate of Industrial and Business Service Management. I have been investing and writing about biotechnology stocks for many years now and have extensive experience writing about the science and companies themselves. I am a contributor to more
Following: 59 Followers: 3433

All Contributions

Latest Posts
33 to 48 of 353 Posts
<<< 1 2 3 4 5 ... 23 >>>
Seattle Genetics Receives FDA Halt On Several Phase 1 Studies
Tuesday, December 27, 2016 9:40 AM EDT
The trial involved a drug that was being evaluated to treat patients with a type of blood cancer known as Acute Myeloid Leukemia.
In this article: SGEN
Read
Aduro Biotech Closes Down Trial On Safety Issue For Main Drug
Monday, October 24, 2016 9:11 PM EDT
Aduro Biotech Fell as much as 22% as soon as news was announced; Ended the day down by only 4%
In this article: ADRO
Read
Array Biopharma Announces Successful Phase 3 Results In Patients With Melanoma
Monday, September 26, 2016 8:05 PM EDT
Shares of ARRY gained 80% after positive phase 3 results
In this article: ARRY
Read
Applied Genetic Technology Tumbles 32% On Eye Study Problems
Tuesday, September 13, 2016 2:49 PM EDT
Applied Genetic Technology tumbled 32% after reporting problems with its gene trial in treating patients with a rare eye disorder.
In this article: AGTC Also: BIIB
Read
Tonix Pharmaceuticals Shares Plummet 50% On Phase 3 Trial Failure
Tuesday, September 6, 2016 9:09 AM EDT
On Tuesday, Tonix Pharmaceuticals announced that it had failed its phase 3 trial in patients with Fibromyalgia. The phase 3 trial, known as the "AFFIRM" trial, failed to meet on the primary endpoint of the study.
In this article: TNXP
Read
Dynavax Sinks 32% As FDA Cancels Its AdComm Meeting
Friday, September 2, 2016 6:35 PM EDT
Review scheduled for mid-November has been postponed on FDA concerns about "ongoing issues" related to Heplisav-B.
In this article: DVAX
Read
Pfizer Pays $14B To Buy Cancer Drug Maker Medivation
Monday, August 22, 2016 1:20 PM EDT
The deal to take out MDVN will pay investors $81.50 a share.
In this article: PFE, MDVN Also: AGN, INCY, VRTX, BMRN, SNY
Read
Cerulean Tumbles On Failed Kidney Cancer Trial
Friday, August 19, 2016 9:44 AM EDT
With this major setback, the company has announced that it will cut 48% of its workforce.
In this article: CERU Also: RHHBY
Read
Aurinia Pharmaceuticals Tumbles After Major Setback
Tuesday, August 16, 2016 4:30 AM EDT
While the trial results were positive the stock still ended up closing lower by 55.75% to $1.81 per share.
In this article: AUPH Also: RHHBY
Read
MEI Pharma Signs Licensing Deal, Soars Higher
Monday, August 8, 2016 10:42 PM EDT
The announcement of MEIP's license agreement with Swiss pharma group Helsinn put the stock up more than 48% premarket, ending the day up just shy of 28%.
In this article: MEIP
Read
Seres Therapeutics Tumbles 70% On Phase 2 Trial Failure
Friday, July 29, 2016 11:00 AM EDT
Seres announced that it had failed to achieve the primary endpoint of a phase 2 clinical trial.
In this article: MCRB
Read
Tobira Therapeutics Plummets 60% On Phase 2b Trial Failure In NASH
Monday, July 25, 2016 7:06 PM EDT
Tobira fails phase 2b trial In NASH but still holds opportunity to run phase 3.
In this article: TBRA
Read
Shares Of Evoke Pharma Tumble 73% On Phase 3 Trial Failure
Monday, July 18, 2016 7:25 PM EDT
When the placebo performs better than the drug, it's never good news ...
In this article: EVOK
Read
Cytrx Shares Fall 66% After Phase 3 Sarcoma Trial Failure
Tuesday, July 12, 2016 8:51 AM EDT
The phase 3 trial recruited up to 433 patients to be treated for second-line soft tissue sarcoma. Shares of the company tumbled as data released showed that patients taking Aldoxorubicin failed to improve.
In this article: CYTR
Read
Juno Tanks 30% Pre-Market After FDA Halts Cancer Trial
Friday, July 8, 2016 9:49 AM EDT
The trial was halted after two patient deaths following the addition of a new preconditioning drug to the trial regimen.
In this article: JUNO Also: KITE, BLUE, ZIOP
Read
Bind Therapeutics Receives Stalking Horse Bid From Pfizer
Sunday, July 3, 2016 10:28 AM EDT
Under the terms of this bid Pfizer has agreed to acquire all of binds assets for a total of $20 million in an all cash-type transaction. The company has been in a rough spot in terms of developing its Accurins platform.
In this article: PFE, BIND Also: AZN, RHHBY, MRK, AMGN
Read
33 to 48 of 353 Posts
<<< 1 2 3 4 5 ... 23 >>>